One patient with a skin/soft tissue tumor who was receiving selumetinib 50 mg BID plus temsirolimus had a confirmed partial response, lasting 117 days; KRAS or EGFR mutations were not detected. This evidence concerns the gene KRAS and soft tissue neoplasm.